Bayer

Overview

Bayer appears in this source as the owner of Monsanto and the corporate party exposed to large Roundup litigation risk.

Current Profile

The episode presents Bayer through litigation and regulatory-preemption risk. David Friedberg says Bayer has paid and reserved large sums for Roundup lawsuits and still faces many outstanding claims. The business issue is whether federal pesticide labeling authority through the Environmental Protection Agency can preempt state failure-to-warn suits.

Key Characteristics

• Parent company connected to Monsanto and Roundup litigation.
• Exposed to large product-liability settlement and reserve claims in the source.
• Dependent on federal-versus-state legal interpretation around pesticide labels.
• Used as a business-law case where regulatory compliance may not end state-law liability.

Evidence

• Litigation exposure: OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze says Bayer has paid and reserved large sums while many cases remain outstanding.
• Legal question: OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze frames the Supreme Court argument around whether EPA labeling preempts state failure-to-warn claims.

Qualifications

The source does not decide the case or independently verify Bayer’s total exposure. The litigation figures and case outcome forecast remain source-scoped.

What Changed

• Created Bayer as the corporate holder of the Monsanto/Roundup litigation risk discussed in the episode.

Relationships

• Monsanto - acquired company and Roundup source in the episode.
• Roundup - pesticide product at the center of the litigation.
• Environmental Protection Agency - federal label authority central to the preemption question.
• Product Liability Federal Preemption - legal concept affecting Bayer’s litigation exposure.